Abstract | BACKGROUND: METHODS AND RESULTS: CONCLUSIONS: The combination of efegatran plus streptokinase is not superior to the current therapy of heparin and accelerated TPA in achieving early patency. In addition, there is no indication that this experimental treatment can achieve better clinical outcome.
|
Authors | A Y Fung, G Lorch, P A Cambier, D Hansen, B G Titus, J S Martin, J J Lee, N R Every, A P Hallstrom, D Stock-Novack, J Scherer, W D Weaver |
Journal | American heart journal
(Am Heart J)
Vol. 138
Issue 4 Pt 1
Pg. 696-704
(Oct 1999)
ISSN: 0002-8703 [Print] United States |
PMID | 10502216
(Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
- Antithrombins
- Fibrinolytic Agents
- Oligopeptides
- Heparin
- Streptokinase
- Tissue Plasminogen Activator
- efegatran
|
Topics |
- Antithrombins
(administration & dosage, therapeutic use)
- Cardiac Catheterization
- Coronary Angiography
- Dose-Response Relationship, Drug
- Drug Therapy, Combination
- Female
- Fibrinolytic Agents
(administration & dosage, therapeutic use)
- Heparin
(administration & dosage, therapeutic use)
- Humans
- Male
- Middle Aged
- Myocardial Infarction
(drug therapy)
- Oligopeptides
(administration & dosage, therapeutic use)
- Streptokinase
(administration & dosage, therapeutic use)
- Tissue Plasminogen Activator
(administration & dosage, therapeutic use)
- Vascular Patency
(drug effects)
|